AHAhmed S. Hejazi

Ahmed S. Hejazi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ahmed S. Hejazi has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Abdulaziz A. Alqarni

    College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Centre, King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Jeddah, Saudi Arabia

    1 shared publication
  • Albaraa T. Alfaraidi

    Ophthalmology Department , King Fahad Armed Forces Hospital , Jeddah , Saudi Arabia , kfafh.org

    1 shared publication
  • Mohammed T. Aqeel

    College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Centre, King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Jeddah, Saudi Arabia

    1 shared publication
  • Turki A. Albalawi

    College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Centre, King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Jeddah, Saudi Arabia

    1 shared publication

Latest Publications

  • Open Access

    Familial Hemophagocytic Lymphohistiocytosis Secondary to PRF1 Mutation

    by Albaraa T. Alfaraidi, Abdulaziz A. Alqarni, Mohammed T. Aqeel, Turki A. Albalawi, Ahmed S. Hejazi

    Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that causes systemic inflammation which can progress to multiorgan failure and death. Symptoms and signs commonly seen in HLH include high fever, hepatosplenomegaly, pancytopenia, and hypertriglyceridemia. This report describes the 8-month clinical course of a 17-year-old male with G6PD deficiency who presented with intermittent high fever of unknown origin for 8months accompanied by pancytopenia and bilateral lower limb weakness. A pathogenic homozygous missense mutation (c.1081A>T p.(Arg361Trp)) in the PRF1 gene was detected by whole exome sequencing (WES). The brain and the whole spine MRI showed leptomeningeal enhancement at different levels involving both the brain and the spine. Therefore, a diagnosis of familial HLH type 2 with CNS involvement was confirmed. Accordingly, treatment with dexamethasone, cyclosporin, and etoposide in addition to intrathecal methotrexate and hydrocortisone was given. The patient showed a dramatic response with significant neurological improvement of the bilateral lower limb weakness. Genetic analysis has helped the patients family with appropriate genetic counselling. This case highlights the importance of immediate treatment with immunosuppressants and the high clinical suspicion of physicians regarding HLH in areas where consanguinity is common.